查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1952481

醫藥和生物製藥用O型圈市場：按材料、產品類型、應用和最終用途分類的全球預測，2026-2032年

O-Rings for Pharmaceutical & Biopharmaceutical Market by Material, Product Type, Application, End Use - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年，醫藥和生物製藥用 O 型圈市場價值為 4.0308 億美元，預計到 2026 年將成長至 4.2907 億美元，複合年成長率為 6.16%，到 ​​2032 年將達到 6.1259 億美元。

主要市場統計數據
基準年 2025 4.0308億美元
預計年份：2026年 4.2907億美元
預測年份：2032年 6.1259億美元
複合年成長率 (%) 6.16%

簡要概述為什麼 O 形圈規格、材料認證和供應商策略對於藥品和生物製藥的安全可靠的生產過程至關重要。

O型圈是製藥和生物製藥生產中至關重要卻又常被忽視的部件，其密封性能直接影響產品安全、製程可靠性和法規遵從性。本執行摘要全面概述了影響關鍵製程設備中使用的彈性體和氟聚合物密封件的材料選擇、合格流程、供應商關係建立以及下游製程性能評估的技術、商業性和法規趨勢。透過將討論置於生產環境、應用需求和分銷機制的框架內，本文檔為需要在性能、潔淨度和供應鏈連續性之間取得平衡的決策者提供了一個統一的觀點。

一次性使用、材料創新、增強的監管可追溯性和供應鏈數位化如何重塑製藥製造中的密封策略？

製藥和生物製藥領域的密封解決方案正經歷一系列變革，重新定義了製造商在整個製程環境中選擇、認證和管理O型圈的方式。尤其值得注意的是向模組化和一次性技術的轉變。這推動了對高純度彈性體和含氟聚合物的需求成長，這些材料能夠顯著減少無菌操作過程中的萃取物和顆粒。同時，聚合物混煉和精密成型技術的進步提高了針對特定熱、化學和機械應力特性而設計的材料的可用性，從而延長了使用壽命並減少了意外停機時間。

本檢驗了修訂後的關稅措施如何促進供應商多元化、材料重新評估和合約保護，從而保護藥品密封件的供應鏈。

美國修訂關稅政策對密封件的採購、設計選擇和供應商選擇產生了一系列營運和策略影響。為因應進口關稅的提高及相關的合規義務，製造商已開始重新評估其全球採購基地和供應商合約條款，以降低投入成本波動並增強供應穩定性。這加速了供應商認證計劃的推進，這些計劃優先考慮區域合作夥伴和垂直整合供應商，因為它們能夠提供更短的前置作業時間、更高的材料來源透明度和更低的總到岸成本波動。

我們按材料等級、最終用途環境、應用、產品類型和分銷管道細分市場洞察，以協助制定認證和籌資策略。

該分析揭示了密封解決方案全系列產品在材料選擇、應用適用性和商業性合作方面受到的詳細影響。按材料分類，市場將三元乙丙橡膠 (EPDM) 分為醫用級和技術級。醫用級 EPDM 優先考慮低萃取性和符合無菌流體接觸的生物相容性標準，而技術級 EPDM 則適用於以成本和廣泛的耐化學性為主要考慮因素的通用密封應用。氟聚合物分為耐高溫配方和標準配方。耐高溫配方可承受高溫滅菌循環和強腐蝕性化學品，而標準配方則需要中等的耐熱性和耐化學性。丁腈橡膠分為食品級和技術級；食品級強調污染物控制和產品接觸相關認證，而技術級則適用於需要耐油和耐磨性的非關鍵密封應用。聚四氟乙烯 (PTFE) 分為模壓製品和異形製品；模製 PTFE 具有優異的化學惰性，適用於定製配置，而異形 PTFE 則可提供標準化外殼的可重複形狀。矽膠分為高純度等級和標準等級。高純度矽專為一次性組件和無菌環境而設計，在這些環境中，低萃取率和一致的機械性能至關重要。

我們評估關鍵地區的監管嚴格程度、供應商生態系統和物流實際情況如何影響材料合格和採購決策。

區域趨勢對美洲、歐洲、中東和非洲以及亞太市場的監管要求、供應商能力和物流限制均有顯著影響。在美洲，成熟的製藥生產體係以及不斷壯大的國內高純度彈性體供應商基礎，為關鍵O型圈組件的近岸外包戰略和更短的認證週期提供了支持。法規結構強調可追溯性和材料安全，促使買家優先選擇擁有完善的文件和檢驗體系的供應商。

深入了解供應商策略，重點關注受控制造、驗證服務和協作設計，可以將密封合作夥伴從普通供應商提升為策略合作夥伴。

為了滿足日益嚴格的客戶期望，密封件供應鏈中的競爭對手和供應商正在整合其在品質系統、技術服務和驗證支援方面的能力。領先的供應商正在投資建造受控生產環境、無塵組裝和專用測試實驗室，以便產生技術團隊和監管機構所需的生物相容性、萃取物和滅菌數據。策略差異化越來越依賴提供端到端可追溯性、批次級檢驗文件以及客製化設計工程支援的能力，從而實現快速合格並降低下游製程的風險。

為了保障生產的連續性和合規性，領導者必須採取切實可行的跨職能措施，加強合格評估，以實現採購多元化，並加強與供應商的夥伴關係。

產業領導者應推行一系列關鍵舉措，以平衡營運韌性與監管技術卓越性。首先，他們應將完善的材料認證通訊協定納入設計管理流程，確保EPDM、氟橡膠、丁腈橡膠、PTFE和矽的選擇均經過萃取測試、滅菌相容性測試以及在特定製程條件下的機械性能測試，從而證明其合理性。同時，他們應優先考慮供應商多元化，整合區域合作夥伴，確保與具備技術能力的供應商建立冗餘機制，這些供應商能夠提供批次級可追溯性以及監管申請所需的文件支援。

為了支援策略決策，我們採用穩健的三角測量研究途徑，結合相關人員訪談、技術文件審查、供應商能力檢查和案例檢驗。

本分析整合了透過三角研究途徑收集的定性和實證資訊，旨在確保其可靠性和對行業相關人員的相關性。主要資訊來源包括對採購經理、品質保證經理、材料科學家和原始設備製造商 (OEM) 設計工程師的結構化訪談，以直接了解材料性能、合格挑戰和供應商能力。此外，還查閱了技術報告、監管指導文件和公開的產品規格，以檢驗接觸密封件的材料特性、檢驗要求和常用合格見解。

為受監管的生產創造可靠的密封解決方案：材料認證、供應商能力和營運一致性的策略整合。

總之，確保製藥和生物製藥生產中的密封完整性需要材料科學、供應商能力和法規遵循三者之間的平衡互動。最有效的策略是結合有針對性的材料認證、策略供應商夥伴關係以及能夠預見監管預期和貿易政策波動的營運實踐。那些在工程、品管和採購部門之間建立規範的跨職能工作流程，並投資於供應商開發和可追溯性的組織，可以實現更可預測的認證進度並減少流程中斷。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：醫藥和生物製藥用O型圈市場：依材料分類

  • EPDM
    • 醫療保健
    • 科技
  • 螢光樹脂
    • 高溫
    • 標準
  • 丁腈橡膠
    • 食品級
    • 技術級
  • PTFE
    • 形成產物
    • 模製產品
  • 矽
    • 高純度
    • 標準

第9章：製藥和生物製藥用O型圈市場：依產品類型分類

  • 風俗
  • 標準產品

第10章：製藥和生物製藥用O型圈市場：依應用領域分類

  • 反應器
  • 混合器
  • 管道
  • 泵浦
  • 閥門

第11章：製藥和生物製藥用O型圈市場：依最終用途分類

  • 生物製藥生產
  • 製藥生產

第12章：製藥和生物製藥用O型圈市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：製藥和生物製藥用O型圈市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：醫藥和生物製藥用O型圈市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國醫藥和生物製藥用O型圈市場

第16章：中國醫藥和生物製藥產業O型圈市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Ames Rubber Manufacturing Company
  • Apple Rubber Products Inc.
  • Bal Seal Engineering, Inc.
  • DuPont de Nemours, Inc.
  • ERIKS SE & Co. KG
  • Freudenberg Medical, LLC
  • Greene, Tweed & Co.
  • IDEX Corporation
  • James Walker & Co Ltd
  • Lauren Manufacturing
  • MARCO Rubber & Plastic Products, Inc.
  • Minnesota Rubber & Plastics
  • Parker Hannifin Corporation
  • Precision Associates, Inc.
  • Saint-Gobain Performance Plastics Corporation
  • Seal & Design, Inc.
  • Semperit AG Holding
  • Trelleborg Sealing Solutions
Product Code: MRR-867BED9A9FB5

The O-Rings for Pharmaceutical & Biopharmaceutical Market was valued at USD 403.08 million in 2025 and is projected to grow to USD 429.07 million in 2026, with a CAGR of 6.16%, reaching USD 612.59 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 403.08 million
Estimated Year [2026] USD 429.07 million
Forecast Year [2032] USD 612.59 million
CAGR (%) 6.16%

A concise orienting perspective on why O-ring specification, material qualification, and supplier strategy are critical for safe and reliable pharmaceutical and biopharmaceutical processing

O-rings serve as foundational yet frequently overlooked components in pharmaceutical and biopharmaceutical production, where sealing integrity directly impacts product safety, process reliability, and regulatory compliance. This executive summary synthesizes the technical, commercial, and regulatory dynamics that shape material selection, qualification pathways, supplier relationships, and downstream application performance for elastomer and fluoropolymer seals used in critical process equipment. By framing the discussion around manufacturing environments, application demands, and distribution mechanisms, the material provides an integrated perspective for decision-makers who must balance performance, cleanliness, and supply continuity.

The narrative emphasizes how compatibility with sterilization methods, resistance to leachables and extractables, and adherence to biocompatibility standards distinguish effective sealing strategies from marginal ones. Moreover, the content foregrounds the interplay between innovation in polymer chemistry, evolving production architectures such as single-use systems, and the intensifying regulatory scrutiny that governs contact materials. Throughout, the intent is to equip technical and commercial leaders with a clear conceptual framework that supports material qualification, supplier engagement, and product lifecycle decisions without relying on high-level market metrics.

How single-use adoption, material innovations, intensified regulatory traceability, and supply chain digitization are reshaping sealing strategies across pharmaceutical production

The landscape for sealing solutions in pharma and biopharma is undergoing a sequence of transformative shifts that are redefining how manufacturers choose, qualify, and manage O-rings across process environments. Foremost among these shifts is the movement toward modular and single-use technologies, which elevates the demand for high-purity elastomers and fluoropolymers that demonstrably minimize extractables and particulates during sterile operations. In parallel, advances in polymer formulations and precision molding have increased the availability of materials engineered for specific thermal, chemical, and mechanical stress profiles, enabling longer service intervals and fewer unplanned outages.

Regulatory emphasis on patient safety has also intensified, prompting more rigorous documentation and traceability requirements for all in-contact components; this has led manufacturers to demand end-to-end evidence of material provenance, test data, and lot-level traceability. Meanwhile, supply chain digitalization and additive quality control enable faster qualification cycles and closer collaboration between OEMs and seal suppliers. Sustainability considerations are beginning to influence procurement criteria as well, with lifecycle assessment and recyclability entering procurement conversations alongside traditional performance metrics. Together, these forces compel organizations to rethink traditional supplier relationships and to prioritize materials, production practices, and logistical arrangements that align with heightened cleanliness, traceability, and resilience expectations.

Assessing how revised tariff measures have driven supplier diversification, material reevaluation, and contractual protections to safeguard pharmaceutical sealing supply chains

The introduction of revised tariff measures in the United States has imposed a set of operational and strategic consequences that reverberate through procurement, design choices, and supplier selection for sealing components. In response to increased import duties and associated compliance obligations, manufacturers have begun to reassess global sourcing footprints and supplier contractual terms to mitigate input cost variability and to strengthen continuity of supply. This has translated into an acceleration of supplier qualification programs that favor regional partners or vertically integrated suppliers who can provide shorter lead times, higher transparency on material origin, and reduced total landed cost volatility.

Moreover, the tariff environment has incentivized product engineers to examine the feasibility of material substitutions or design optimizations that lower dependency on tariff-impacted imports without compromising biocompatibility or sterilization resistance. Procurement teams are increasingly structuring longer-term agreements with diversified supplier panels and incorporating clauses that share the burden of tariff-related cost fluctuations. At the same time, logistics and compliance teams prioritize documentation and tariff classification accuracy to avoid inadvertent penalties. Overall, the combined effect of tariff adjustments is a stronger emphasis on supply chain resilience, regional capability assessment, and contractual protections that collectively reduce exposure to trade-policy shifts while preserving the necessary quality attributes for critical sealing applications.

Deconstructing segmentation insights across material grades, end-use environments, applications, product typologies, and distribution channels to inform qualification and sourcing strategies

Segmentation-driven analysis reveals granular implications for material selection, application suitability, and commercial engagement across the portfolio of sealing solutions. When examined by material, the market differentiates EPDM into medical and technical grades, with medical-grade EPDM prioritizing low extractables and compliance to biocompatibility standards for sterile fluid contact, while technical EPDM addresses general utility sealing where cost and broad chemical resistance are primary considerations. Fluorocarbon compounds distinguish between high-temperature formulations engineered to withstand elevated sterilization cycles and aggressive chemistries, and standard fluorocarbon variants used where moderate thermal and chemical resilience is sufficient. Nitrile is segmented into food-grade and technical-grade offerings, where food-grade nitrile focuses on contaminant control and relevant certifications for product contact, and technical-grade nitrile serves non-critical sealing needs that demand oil and abrasion resistance. PTFE is further described as formed and molded types, with formed PTFE offering superior chemical inertness for custom configurations and molded PTFE enabling repeatable geometries for standardized housings. Silicone separates into high-purity and standard classes, with high-purity silicone targeted to single-use assemblies and sterile environments where low extractables and consistent mechanical performance are essential.

Across end use, there is a clear distinction between biopharmaceutical manufacturing and pharmaceutical manufacturing, as the former often requires tighter controls on extractables, more frequent single-use integration, and specialized material certifications, while the latter balances legacy stainless-steel process compatibility with sterilization regimes that may tolerate different elastomer chemistries. Application-driven nuances matter as well: seals used in bioreactors face challenges from agitation, cellular interaction, and sterilization cycles that demand specific elastomer resilience, whereas mixers, pipelines, pumps, and valves each impose distinct compression set, abrasion, and chemical exposure profiles that influence material and design selection. Product type considerations-custom versus standard-determine the extent of design validation, tool investment, and qualification testing, with custom solutions often required for atypical flange designs or unique process interfaces, and standard types supporting higher-volume, repeatable configurations. Distribution channel dynamics influence procurement and support models, where direct sales enable closer technical collaboration and traceability, distributors offer broad availability and regional reach, and e-commerce platforms provide convenience and expedited replenishment for standardized parts. These layered segmentation perspectives shape how technical teams and procurement leaders prioritize qualification pathways, inventory strategies, and supplier partnerships to align material performance with operational and regulatory demands.

Evaluating how regional regulatory rigor, supplier ecosystems, and logistical realities across major global regions influence material qualification and sourcing decisions

Regional dynamics exert a strong influence on regulatory expectations, supplier capabilities, and logistical constraints across the Americas, Europe, Middle East & Africa, and Asia-Pacific markets. In the Americas, manufacturing clusters combine mature pharmaceutical production with an increasingly robust domestic supplier base for high-purity elastomers, which supports nearshoring strategies and shorter qualification cycles for critical O-ring components. The regulatory framework emphasizes traceability and material safety, encouraging buyers to prioritize suppliers with demonstrated documentation and testing regimes.

Across Europe, the Middle East & Africa, regulatory harmonization and rigorous quality systems drive demand for certified materials and process validation, while proximity to precision polymer converters and specialized engineering service providers enables customized sealing solutions. In the Asia-Pacific region, a vibrant manufacturing ecosystem offers scale advantages and diverse material sources, yet buyers must carefully navigate variable regulatory standards and supplier quality practices. Consequently, organizations evaluate regional sourcing not only on cost and capacity metrics but also on supplier auditability, shipping reliability, and the ability to deliver validated documentation for regulatory submissions. These regional contrasts influence how companies structure supplier portfolios, design qualification protocols, and operationalize inventory buffers to mitigate geographic and policy-driven risks.

Insights into supplier strategies emphasizing controlled manufacturing, validation services, and collaborative design that elevate sealing partners from vendors to strategic collaborators

Competitors and suppliers in the sealing supply chain are consolidating capabilities around quality systems, technical service, and validation support to meet increasingly stringent customer expectations. Leading suppliers invest in controlled manufacturing environments, cleanroom assembly, and dedicated testing laboratories that can generate the biocompatibility, extractables, and sterilization data required by technical teams and regulators. Strategic differentiation increasingly rests on the ability to provide end-to-end traceability, lot-level testing documentation, and engineering support for custom designs, enabling faster qualification and reduced downstream risk.

Partnership models are evolving to include active collaboration in early-stage design and validation phases, with some suppliers offering co-development arrangements, sample programs, and on-demand testing to accelerate client approval. At the same time, suppliers that integrate vertically-combining polymer compounding, precision molding, and assembly-are positioned to reduce lead-time variability and to take joint ownership of quality outcomes. Service offerings such as rapid prototyping, failure analysis, and extended certification packages further distinguish firms that seek to be strategic partners rather than transactional vendors. For buyers, this supplier behavior underscores the value of rigorous supplier audits, performance-based contracts, and scorecards that align technical expectations with commercial terms.

Practical, cross-functional actions for leaders to tighten qualification, diversify sourcing, and strengthen supplier partnerships to protect production continuity and compliance

Industry leaders should pursue a set of targeted actions that reconcile operational resilience with regulatory and technical excellence. First, embed robust material qualification protocols into design control processes, ensuring that choices for EPDM, fluorocarbon, nitrile, PTFE, and silicone are justified by extractables testing, sterilization compatibility, and mechanical performance under process-specific conditions. Concurrently, prioritize supplier diversification that combines regional partners for redundancy with technically capable suppliers able to provide lot-level traceability and documentary support for regulatory filings.

Leaders must also invest in closer integration between engineering, quality, and procurement functions to shorten qualification cycles; this can include cross-functional teams that jointly run risk assessments, design-of-experiments for material substitution, and accelerated validation pathways. From a sourcing perspective, negotiate contracts that allocate tariff exposure and include service-level agreements tied to delivery performance and documentation timeliness. Operational enhancements such as establishing safety stocks for critical SKUs, mapping alternative production routes for bespoke components, and developing rapid-response modification processes for seals will reduce downtime risk. Finally, commit to supplier development programs that fund capability upgrades-such as cleanroom certification or additional testing capacity-to create mutually beneficial partnerships that secure both performance and supply continuity.

A robust triangulated research approach combining stakeholder interviews, technical document review, supplier capability checks, and case validations to support strategic decisions

This analysis synthesizes qualitative and empirical inputs gathered through a triangulated research approach designed to ensure reliability and relevance for industry stakeholders. Primary data sources included structured interviews with procurement leaders, quality assurance managers, materials scientists, and OEM design engineers to capture firsthand perspectives on material performance, qualification pain points, and supplier capabilities. These qualitative insights were complemented by review of technical reports, regulatory guidance documents, and publicly available product specifications to verify material properties, testing requirements, and common qualification pathways for in-contact seals.

To validate assertions about supplier behavior and regional capabilities, the methodology incorporated audit summaries, supplier capability statements, and engineering case studies that illustrate real-world qualification and failure-mode scenarios. Data synthesis emphasized cross-validation across multiple sources to reduce bias and to identify consistent patterns. Finally, limitations are acknowledged: analysis focuses on technical and operational dynamics rather than numeric market sizing, and rapidly evolving policy or material innovations could alter some operational recommendations, so stakeholders are encouraged to treat the findings as a strategic foundation supplemented by ongoing supplier dialogues and technical verification.

Strategic synthesis highlighting how material qualification, supplier capability, and operational alignment create resilient sealing solutions for regulated production

In closing, ensuring sealing integrity in pharmaceutical and biopharmaceutical operations requires a balanced interplay of material science, supplier capability, and regulatory alignment. The most effective strategies combine targeted material qualification, strategic supplier partnerships, and operational practices that anticipate both regulatory expectations and trade-policy fluctuations. Organizations that formalize cross-functional workflows between engineering, quality, and procurement, and that invest in supplier development and traceability, will realize more predictable qualification timelines and fewer process disruptions.

As the industry advances toward single-use adoption, heightened traceability, and sustainability considerations, decision-makers should treat O-ring selection and supplier relationships as strategic assets rather than routine procurement items. This perspective enables more resilient production ecosystems, minimizes product risk, and creates a foundation for continuous improvement in sealing performance and regulatory readiness.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. O-Rings for Pharmaceutical & Biopharmaceutical Market, by Material

  • 8.1. EPDM
    • 8.1.1. Medical
    • 8.1.2. Technical
  • 8.2. Fluorocarbon
    • 8.2.1. High Temperature
    • 8.2.2. Standard
  • 8.3. Nitrile
    • 8.3.1. Food Grade
    • 8.3.2. Technical Grade
  • 8.4. PTFE
    • 8.4.1. Formed
    • 8.4.2. Molded
  • 8.5. Silicone
    • 8.5.1. High Purity
    • 8.5.2. Standard

9. O-Rings for Pharmaceutical & Biopharmaceutical Market, by Product Type

  • 9.1. Custom
  • 9.2. Standard

10. O-Rings for Pharmaceutical & Biopharmaceutical Market, by Application

  • 10.1. Bioreactors
  • 10.2. Mixers
  • 10.3. Pipelines
  • 10.4. Pumps
  • 10.5. Valves

11. O-Rings for Pharmaceutical & Biopharmaceutical Market, by End Use

  • 11.1. Biopharmaceutical Manufacturing
  • 11.2. Pharmaceutical Manufacturing

12. O-Rings for Pharmaceutical & Biopharmaceutical Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. O-Rings for Pharmaceutical & Biopharmaceutical Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. O-Rings for Pharmaceutical & Biopharmaceutical Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States O-Rings for Pharmaceutical & Biopharmaceutical Market

16. China O-Rings for Pharmaceutical & Biopharmaceutical Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Ames Rubber Manufacturing Company
  • 17.6. Apple Rubber Products Inc.
  • 17.7. Bal Seal Engineering, Inc.
  • 17.8. DuPont de Nemours, Inc.
  • 17.9. ERIKS SE & Co. KG
  • 17.10. Freudenberg Medical, LLC
  • 17.11. Greene, Tweed & Co.
  • 17.12. IDEX Corporation
  • 17.13. James Walker & Co Ltd
  • 17.14. Lauren Manufacturing
  • 17.15. MARCO Rubber & Plastic Products, Inc.
  • 17.16. Minnesota Rubber & Plastics
  • 17.17. Parker Hannifin Corporation
  • 17.18. Precision Associates, Inc.
  • 17.19. Saint-Gobain Performance Plastics Corporation
  • 17.20. Seal & Design, Inc.
  • 17.21. Semperit AG Holding
  • 17.22. Trelleborg Sealing Solutions

LIST OF FIGURES

  • FIGURE 1. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY EPDM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY EPDM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY EPDM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY EPDM, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY MEDICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY MEDICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY MEDICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY TECHNICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY TECHNICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY TECHNICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY FLUOROCARBON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY FLUOROCARBON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY FLUOROCARBON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY FLUOROCARBON, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY HIGH TEMPERATURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY HIGH TEMPERATURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY HIGH TEMPERATURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY STANDARD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY STANDARD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY STANDARD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY NITRILE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY NITRILE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY NITRILE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY NITRILE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY FOOD GRADE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY FOOD GRADE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY FOOD GRADE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY TECHNICAL GRADE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY TECHNICAL GRADE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY TECHNICAL GRADE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PTFE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PTFE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PTFE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PTFE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY FORMED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY FORMED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY FORMED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY MOLDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY MOLDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY MOLDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY SILICONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY SILICONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY SILICONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY SILICONE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY HIGH PURITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY HIGH PURITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY HIGH PURITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY STANDARD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY STANDARD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY STANDARD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY CUSTOM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY CUSTOM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY CUSTOM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY STANDARD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY STANDARD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY STANDARD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY BIOREACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY BIOREACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY MIXERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY MIXERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY MIXERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PIPELINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PIPELINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PIPELINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY VALVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY VALVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY VALVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY BIOPHARMACEUTICAL MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY BIOPHARMACEUTICAL MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY BIOPHARMACEUTICAL MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY EPDM, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY FLUOROCARBON, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY NITRILE, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PTFE, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY SILICONE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY EPDM, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY FLUOROCARBON, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY NITRILE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PTFE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY SILICONE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY EPDM, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY FLUOROCARBON, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY NITRILE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PTFE, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY SILICONE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY EPDM, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY FLUOROCARBON, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY NITRILE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PTFE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY SILICONE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY EPDM, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY FLUOROCARBON, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY NITRILE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PTFE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY SILICONE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY EPDM, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY FLUOROCARBON, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY NITRILE, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PTFE, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY SILICONE, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY EPDM, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY FLUOROCARBON, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY NITRILE, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PTFE, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY SILICONE, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY EPDM, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY FLUOROCARBON, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY NITRILE, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PTFE, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY SILICONE, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY EPDM, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY FLUOROCARBON, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY NITRILE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PTFE, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY SILICONE, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GCC O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 177. GCC O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY EPDM, 2018-2032 (USD MILLION)
  • TABLE 178. GCC O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY FLUOROCARBON, 2018-2032 (USD MILLION)
  • TABLE 179. GCC O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY NITRILE, 2018-2032 (USD MILLION)
  • TABLE 180. GCC O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PTFE, 2018-2032 (USD MILLION)
  • TABLE 181. GCC O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY SILICONE, 2018-2032 (USD MILLION)
  • TABLE 182. GCC O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. GCC O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. GCC O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY EPDM, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY FLUOROCARBON, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY NITRILE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PTFE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY SILICONE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY EPDM, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY FLUOROCARBON, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY NITRILE, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PTFE, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY SILICONE, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 205. G7 O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. G7 O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 207. G7 O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY EPDM, 2018-2032 (USD MILLION)
  • TABLE 208. G7 O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY FLUOROCARBON, 2018-2032 (USD MILLION)
  • TABLE 209. G7 O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY NITRILE, 2018-2032 (USD MILLION)
  • TABLE 210. G7 O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PTFE, 2018-2032 (USD MILLION)
  • TABLE 211. G7 O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY SILICONE, 2018-2032 (USD MILLION)
  • TABLE 212. G7 O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. G7 O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. G7 O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 215. NATO O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. NATO O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 217. NATO O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY EPDM, 2018-2032 (USD MILLION)
  • TABLE 218. NATO O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY FLUOROCARBON, 2018-2032 (USD MILLION)
  • TABLE 219. NATO O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY NITRILE, 2018-2032 (USD MILLION)
  • TABLE 220. NATO O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PTFE, 2018-2032 (USD MILLION)
  • TABLE 221. NATO O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY SILICONE, 2018-2032 (USD MILLION)
  • TABLE 222. NATO O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. NATO O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. NATO O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY EPDM, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY FLUOROCARBON, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY NITRILE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PTFE, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY SILICONE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY EPDM, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY FLUOROCARBON, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY NITRILE, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PTFE, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY SILICONE, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA O-RINGS FOR PHARMACEUTICAL & BIOPHARMACEUTICAL MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)